Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
HyperScript™ Reverse Transcriptase for qPCR
2026-08-23
HyperScript™ Reverse Transcriptase supports reliable RNA to cDNA conversion when structured templates, long transcripts, or low-abundance targets challenge routine workflows. This guide translates intestinal stem cell stress research into practical cDNA synthesis for qPCR, assay design, and troubleshooting decisions.
-
Tacrine hydrochloride hydrate: Assay Guide
2026-08-22
A scenario-based guide to using Tacrine hydrochloride hydrate (SKU C6449) in cholinesterase, cell-viability, proliferation, and neuroprotection workflows. It connects concentration planning, solvent controls, storage, interpretation, and vendor-selection criteria to evidence from the product dossier and peer-reviewed literature.
-
GOB-38 in Elizabethkingia: Substrate Specificity
2026-08-22
The reference study characterizes GOB-38, a B3-Q metallo-β-lactamase from Elizabethkingia anophelis, and shows that it hydrolyzes a broad range of β-lactam antibiotics, including carbapenems. Its recombinant expression, purified-enzyme analysis, genomic investigation, and co-culture experiments connect enzyme structure with resistance phenotypes and highlight the need to distinguish rapid β-lactamase detection from detailed substrate-specificity analysis.
-
Lapatinib (GW572016): EGFR and HER2 Research
2026-08-21
Lapatinib, also called GW572016, is a reversible small-molecule inhibitor of EGFR and HER2 receptor tyrosine kinases. Its biochemical potency, cell-model activity, handling profile, and tumor-model benchmark support targeted cancer therapy research while requiring careful separation of assay potency from clinical efficacy.
-
Topotecan for Ovarian Cancer: Evidence Review
2026-08-20
This Cochrane review evaluated whether adding Topotecan, also known as SKF104864, to standard ovarian cancer chemotherapy improves survival or disease control. Its main contribution was a structured comparison of overall survival, progression outcomes, and toxicity, showing that greater treatment intensity did not establish a clear survival advantage and raised important safety considerations.
-
Tacrine hydrochloride hydrate in AD assays
2026-08-20
This scenario-based guide explains how Tacrine hydrochloride hydrate supports cholinesterase, cell viability, and neuroprotection workflows in Alzheimer's disease research. It covers concentration selection, solvent controls, interpretation, storage, and vendor-selection considerations for SKU C6449.
-
EHEC Delays Danazol-Induced Precocious Puberty
2026-08-19
The 2025 reference study tests an Eclipta prostrata–Hordeum vulgare extract complex in rat models of precocious puberty triggered by Danazol or a high-fat diet. By combining developmental, ovarian, molecular, and body-weight endpoints, the work links delayed vaginal opening and reduced ovarian maturation with attenuation of hypothalamic GnRH expression, while also identifying important limits for translation to human endocrine disease.
-
Epacadostat: From IDO1 Mechanism to Translation
2026-08-19
A translational framework for using Epacadostat (INCB024360) to connect IDO1 inhibition, standardized whole-blood immunometabolism, and combination immuno-oncology research.
-
Cy5 TSA Fluorescence System Kit: Workflow Guide
2026-08-18
The Cy5 TSA Fluorescence System Kit converts weak HRP activity into a bright, spatially confined Cy5 signal for challenging IHC, ICC, and FISH experiments. This practical guide connects the chemistry to liver-development imaging, low-abundance target detection, multiplex planning, and troubleshooting.
-
Self-Amplifying RNA Vaccines for Influenza: Study Insights
2026-08-18
Huang and colleagues compared modified mRNA, self-amplifying RNA, and circular RNA vaccine strategies across influenza A and B models. The study identifies self-amplifying RNA as a dose-sparing platform that maintained strong antibody responses and protected mice from influenza B challenge at a dose where conventional mRNA performed poorly.
-
Macrophage EP4 and CD36 in Atherosclerosis
2026-08-17
The reference study identifies macrophage EP4 deficiency as a driver of atherosclerosis progression, linking loss of EP4 signaling to increased CD36 expression, lipid uptake, foam cell formation, and M1-like inflammatory polarization. Its integrated mouse, cellular, transcriptomic, and proteomic design provides a mechanistic framework for interpreting how prostaglandin signaling influences plaque development and stability.
-
Sumatriptan Metabolism Revisited: CYP and MAO A
2026-08-17
The reference study challenges the conventional view that sumatriptan is metabolized exclusively through MAO A-mediated oxidative deamination. Using recombinant human enzymes and HPLC–MS, it demonstrates parallel CYP-mediated N-demethylation followed by MAO A metabolism, refining how sumatriptan biotransformation should be interpreted in pharmacokinetic research.
-
Annexin V-PE Apoptosis Detection Kit for Monocytes
2026-08-16
Use the Annexin V-PE Apoptosis Detection Kit to add a rapid, fixation-free cell-death endpoint to inflammatory monocyte experiments. The workflow complements cytokine, surface-marker, and TLR4 measurements by showing whether a treatment changes inflammation without simply reducing cell viability.
-
Protease Inhibitor Cocktail for Rice Phosphorylation Assays
2026-08-15
Protect phosphorylation-sensitive rice proteins during extraction, Western blotting, co-immunoprecipitation, and kinase assays without chelating essential divalent cations. This EDTA-free workflow is especially useful for investigating calcium-dependent kinase signaling under heat and pathogen stress.
-
Sulfisomidine Inhibition of Human PON1
2026-08-14
The 2017 study in the Journal of Biochemical and Molecular Toxicology compared six sulfonamides as inhibitors of purified human serum paraoxonase 1 (hPON1), combining inhibition kinetics with molecular docking. Sulfisomidine showed mixed-type inhibition, providing a useful biochemical model for examining how sulfonamide structure can influence an enzyme associated with oxidative protection and lipoprotein metabolism.